CARDIOQUIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cardioquin, and when can generic versions of Cardioquin launch?
Cardioquin is a drug marketed by Pharm Res Assoc and is included in one NDA.
The generic ingredient in CARDIOQUIN is quinidine polygalacturonate. There is one drug master file entry for this compound. Additional details are available on the quinidine polygalacturonate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CARDIOQUIN?
- What are the global sales for CARDIOQUIN?
- What is Average Wholesale Price for CARDIOQUIN?
Summary for CARDIOQUIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 4 |
| DailyMed Link: | CARDIOQUIN at DailyMed |
US Patents and Regulatory Information for CARDIOQUIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharm Res Assoc | CARDIOQUIN | quinidine polygalacturonate | TABLET;ORAL | 011642-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
